M
Maya Gottfried
Researcher at Meir Medical Center
Publications - 120
Citations - 14309
Maya Gottfried is an academic researcher from Meir Medical Center. The author has contributed to research in topics: Lung cancer & Pembrolizumab. The author has an hindex of 32, co-authored 110 publications receiving 9903 citations. Previous affiliations of Maya Gottfried include Tel Aviv University & Sheba Medical Center.
Papers
More filters
Journal ArticleDOI
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck,Delvys Rodriguez-Abreu,Andrew G. Robinson,Rina Hui,Tibor Csőszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinead Cuffe,Mary O'Brien,Suman Rao,Katsuyuki Hotta,Melanie A. Leiby,Gregory M. Lubiniecki,Yue Shentu,Reshma A. Rangwala,Julie R. Brahmer +17 more
TL;DR: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express PD-L1 as mentioned in this paper.
Journal ArticleDOI
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Aurélien Marabelle,Dung T. Le,Paolo A. Ascierto,Anna Maria Di Giacomo,Ana De Jesus-Acosta,Jean Pierre Delord,Ravit Geva,Maya Gottfried,Nicolas Penel,Aaron R. Hansen,Sarina Anne Piha-Paul,Toshihiko Doi,Bo Gao,Hyun Cheol Chung,Jose A. Lopez-Martin,Yung-Jue Bang,Ronnie Shapira Frommer,Manisha H. Shah,Razi Ghori,Andrew K. Joe,Scott K. Pruitt,Luis A. Diaz +21 more
TL;DR: The study demonstrates the clinical benefit of anti-programmed death-1 therapy with pembrolizumab among patients with previously treated unresectable or metastatic MSI-H/dMMR noncolorectal cancer.
Journal ArticleDOI
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck,Delvys Rodriguez-Abreu,Andrew G. Robinson,Rina Hui,Tibor Csoszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinead Cuffe,Mary O'Brien,Suman Rao,Katsuyuki Hotta,Kristel Vandormael,Antonio Riccio,J. Yang,M. Catherine Pietanza,Julie R. Brahmer +17 more
TL;DR: With prolonged follow-up, first-line pembrolizumab monotherapy continues to demonstrate an OS benefit over chemotherapy in patients with previously untreated, advanced NSCLC without EGFR/ALK aberrations, despite crossover from the control arm to pembrolezumab as subsequent therapy.
Journal ArticleDOI
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Martin Reck,Rolf Kaiser,Anders Mellemgaard,Jean-Yves Douillard,Sergey Orlov,Maciej Krzakowski,Joachim von Pawel,Maya Gottfried,Igor Bondarenko,Meilin Liao,Claudia-Nanette Gann,José Barrueco,Birgit Gaschler-Markefski,Silvia Novello +13 more
TL;DR: Overall survival was significantly improved for patients with adenocarcinoma histology who progressed within 9 months after start of first-line treatment in the docetaxel plus nintedanib group, compared with those in theDocetaxe plus placebo group.
Journal ArticleDOI
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >= 50%
Martin Reck,Delvys Rodriguez-Abreu,Andrew G. Robinson,Rina Hui,Tibor Csőszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinead Cuffe,Mary O'Brien,Suman Rao,Katsuyuki Hotta,Ticiana A. Leal,Jonathan W. Riess,Erin Jensen,Bin Zhao,M. Catherine Pietanza,Julie R. Brahmer +18 more
TL;DR: The first 5-year follow-up of any first-line phase III immunotherapy trial for non-small-cell lung cancer (NSCLC) was reported in this article.